With regard to the tumour, this contained a pathogenic somatic neurofibromatosis 2 (NF2) frameshift mutation and pathogenic loss of function somatic BAP1 mutation, which is in line with the immunohistochemistry result showing loss of nuclear labelling for BAP1. This evidence concerns the gene BAP1 and neoplasm.